These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 29928422)

  • 21. [Detection of epidermal growth factor receptor gene mutations in non-small cell lung cancer using bi-loop probe specific primer quantitative PCR].
    Wang LS; Zhang Y; Lu XJ; Lu HJ; Zhou L; Wang YS; Deng L; Huang MJ; Peng F; Wang J; Ren L; Hou M; Li L; Xu Y; Ying BW; Lu Y
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):667-70. PubMed ID: 22321544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Analysis of epidermal growth factor receptor mutations and its clinico-pathologic characteristics of the primary lung adenocarcinoma in Xinjiang Uighur Autonomous Region].
    Ma XM; Cao YZ; Ji WL; Zhao F; Fang XZ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Aug; 48(4):663-666. PubMed ID: 29263509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
    Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
    Kozu Y; Tsuta K; Kohno T; Sekine I; Yoshida A; Watanabe S; Tamura T; Yokota J; Suzuki K; Asamura H; Furuta K; Tsuda H
    Lung Cancer; 2011 Jul; 73(1):45-50. PubMed ID: 21129809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
    Zhang Y; Wang Q; Han ZG; Shan L
    Asian Pac J Cancer Prev; 2013; 14(5):2879-83. PubMed ID: 23803047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China.
    Wei WE; Mao NQ; Ning SF; Li JL; Liu HZ; Xie T; Zhong JH; Feng Y; Wei CH; Zhang LT
    PLoS One; 2016; 11(12):e0168795. PubMed ID: 27992557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of the epidermal growth factor receptor mutation status and differences among molecular subgroups in surgically resected lung microinvasive adenocarcinoma.
    Li M; Li C; Ke L; Zhan M; Cheng M
    Oncol Lett; 2018 Dec; 16(6):7057-7067. PubMed ID: 30546439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
    Kim DW; Lee SH; Lee JS; Lee MA; Kang JH; Kim SY; Shin SW; Kim HK; Heo DS
    Lung Cancer; 2011 Jan; 71(1):65-9. PubMed ID: 20430469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Divergent epidermal growth factor receptor mutation patterns between smokers and non-smokers with lung adenocarcinoma.
    Tseng JS; Wang CL; Yang TY; Chen CY; Yang CT; Chen KC; Hsu KH; Tsai CR; Chang GC
    Lung Cancer; 2015 Dec; 90(3):472-6. PubMed ID: 26474957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR mutations subset in Chinese lung squamous cell carcinoma patients.
    Sun Y; Yin X; Wen MM; Zhang J; Wang XJ; Xia JH; Zhang YN; Zhang ZP; Li XF
    Mol Med Rep; 2018 Jun; 17(6):7575-7584. PubMed ID: 29620244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China.
    Wang JL; Fu YD; Gao YH; Li XP; Xiong Q; Li R; Hou B; Huang RS; Wang JF; Zhang JK; Lv JL; Zhang C; Li HW
    Genes Environ; 2022 May; 44(1):17. PubMed ID: 35606799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment: a meta-analysis.
    Sheng M; Wang F; Zhao Y; Li S; Wang X; Shou T; Luo Y; Tang W
    Eur J Clin Pharmacol; 2016 Jan; 72(1):1-11. PubMed ID: 26490356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel EGFR mutation-specific antibodies for lung adenocarcinoma: highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry.
    Seo AN; Park TI; Jin Y; Sun PL; Kim H; Chang H; Chung JH
    Lung Cancer; 2014 Mar; 83(3):316-23. PubMed ID: 24412618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Relationship of epidermal growth factor receptor gene mutations, clinicopathologic features and prognosis in patients with non-small cell lung cancer].
    Fan MJ; Li HG; Lü ZQ; Zhang HZ; Shen XM
    Zhonghua Bing Li Xue Za Zhi; 2011 Oct; 40(10):679-82. PubMed ID: 22321547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.